Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer

PURPOSE: Treatment of advanced pancreatic cancer with a single therapeutic at a maximal dose has been largely ineffective at increasing survival. Combination therapies are commonly studied but often limited by toxicity. We previously showed that low-dose multiagent therapy with gemcitabine, docetaxe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilbur, H. Catherine, Durham, Jennifer N., Lim, Su Jin, Purtell, Katrina, Bever, Katherine M., Laheru, Daniel A., De Jesus-Acosta, Ana, Azad, Nilofer S., Wilt, Bradley, Diaz, Luis A., Le, Dung T., Wang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461640/
https://www.ncbi.nlm.nih.gov/pubmed/37645623
http://dx.doi.org/10.1158/2767-9764.CRC-23-0230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461640/
https://www.ncbi.nlm.nih.gov/pubmed/37645623
http://dx.doi.org/10.1158/2767-9764.CRC-23-0230

Ejemplares similares